Abstracts tagged "B-Cell Targets"

Abstract Number: 1533 • ACR Convergence 2024
Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B Cells in Preclinical Models of Autoimmune Disease
Racquel Domingo-Gonzalez¹, Isabelle Baribaud², Shrishti Tyagi¹, Kevin Hart¹, Ryan Eberwine², Angus Sinclair¹, Albert Candia¹, Bruce Keyt¹, Merle Elloso², Maya Kotturi¹ and Mary Beth Harler¹, ¹IGM Biosciences, Inc., Mountain View, CA, ²IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cell depletion therapy (BCDT) with conventional IgG mAbs has been employed for the treatment of autoimmune (AI) disease for ~20 years; however, many…
Abstract Number: 2257 • ACR Convergence 2024
Comparison of the Safety and Effectiveness of Originator Rituximab (Mabthera®) versus Biosimilar (Riximyo®) in Rheumatoid Arthritis: A Retrospective Unicentric Analysis
Barbara Bayeh¹, Fanny Neira¹, Karina Bonfiglioli¹, Nadia Aikawa², ANA PAULA ASSAD¹, Renata Miossi¹, Fernando Souza³, Carlos Emilio Insfran Echauri¹, Henrique Giardini¹, Emily Figueiredo Neves Yuki¹, Henrique Carriço Da Silva¹, Andre Franco¹, Diogo Domiciano¹, Julio Moraes⁴, Eloisa Bonfa¹, Carla Goncalves Schahin Saad³, Ana Cristina Medeiros-Ribeiro⁵ and Andrea Shimabuco³, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil
Background/Purpose: Immunobiological drugs emerged as a revolutionary option for treating inflammatory chronic rheumatic diseases, particularly rheumatoid arthritis (RA). However, the extremely high costs associated with…
Abstract Number: 0004 • ACR Convergence 2024
Beyond Antibodies and CAR-T: Topologically Engineered, Superdimeric Antibody NK Engagers and T Cell Engagers for B Cell Depletion Demonstrating Cooperative Binding to Target and Effector Cells
Daniel Capon, Larisa Troitskaya, Marina Fomin, Brendon Frank, Ursula Edman, Benjamin Capon, Brian Law, Steven Chapin, Gavin Lewis, Malcolm Gefter, Juha Punnonen and Nelson Chan, Hinge Bio, Inc., Burlingame, CA
Background/Purpose: The dramatic demonstration of CD19 CAR-T efficacy in systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis by Georg Schett and colleagues (F.…
Abstract Number: 0513 • ACR Convergence 2024
Effects of Cumulative Rituximab Exposure in Patients with Rheumatoid Arthritis: Results from Cohort at a Tertiary Academic Health Care Setting
Ioasaf Karafotias¹, Maryam Adas¹, Katie Bechman¹, Nicholas Williamson¹, Mark Hughes¹, Daksh Mehta², Ritika Roy¹, Sam Norton³ and James Galloway⁴, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom, ³King's College London, London, England, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Rituximab targets CD20-positive B cells and is used to treat rheumatoid arthritis (RA). B cell depletion may result in hypogammaglobulinemia. Hypogammaglobulinemia is a risk…
Abstract Number: 1541 • ACR Convergence 2024
Effect of Rituximab on Long-term Damage Acquisition in Patients with Systemic Lupus Erythematosus
Amanda Brito¹, Teresa Moitinho de Almeida², Sofia Miranda³, Miriam Barreto Baié¹, Daniel Calado³ and David Isenberg⁴, ¹Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil, ²Unidade Local de Saúde de Lisboa Ocidental, Lisboa, Portugal, ³Hospital do Divino Espírito Santo, Ponta Delgada, Portugal, ⁴University College London, London, United Kingdom
Background/Purpose: B-cell depletion has been used to treat patients with systemic lupus erythematosus (SLE) for over twenty years, but we still lack studies that evaluate…
Abstract Number: 2425 • ACR Convergence 2024
Ianalumab Induced Durable Depletion of Circulating B Cell Subsets and Associated Changes in B Cell and Neutrophil Transcriptomic and Proteomic Profiles in Patients with Systemic Lupus Erythematosus: 52-Week Treatment Results from a Phase 2 Trial
Marianna Rowlands¹, Thomas Dörner², Diego Saldana Miranda³, Justin McMullen³, Aida Santos da Costa³, Ulrike Sommer³, Rainer Hillenbrand³, Andre Nogueira da Costa³, Claire Bonal³, Isabelle Isnardi³, Edward Khokhlovich¹ and Stephen J Oliver³, ¹Biomedical Research, Novartis, Cambridge, MA, ²Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ³Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab (VAY736), a B cell activating factor receptor (BAFFR) targeting mAb, depletes B cells via both antibody dependent cellular cytotoxicity and blockade of BAFF:BAFFR…
Abstract Number: 0006 • ACR Convergence 2024
NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
Mark Noviski¹, Jun Ma¹, Nivetha Brathaban¹, Aishwarya Kumar¹, Dhwani Haria¹, Jenny McKinnell¹, Robert Cass¹, Frederick Cohen¹, Davorka Messmer², Gwenn Hansen¹ and Ryan Rountree¹, ¹Nurix Therapeutics, San Francisco, CA, ²Nurix Therapeutics, San Diego, CA
Background/Purpose: Bruton’s tyrosine kinase (BTK) mediates signaling downstream of the B cell receptor (BCR), toll-like receptors (TLRs), and Fc receptors (FcRs). This makes BTK an…
Abstract Number: 0536 • ACR Convergence 2024
A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease
Claire Mukashyaka¹, Xiaodong Wang¹, Sujata Arora¹, Mason Yamashita¹, Allen Poma¹ and Tanya Fischer², ¹Zenas BioPharma, Waltham, MA, ²Zenas BioPharma, Waltham, CA
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefit…
Abstract Number: 1551 • ACR Convergence 2024
Efficacy of Belimumab on Different Phenotypes of Joint and Skin Manifestations of Systemic Lupus Erythematosus: Preliminary Data from a Multicenter, Nationwide, Cohort of Patients: The BElimumab in Real Life Setting Study-New Joint and Skin (BeRLISS-NeJS)
Luca Iaccarino¹, Marisol Bracalenti², Alberto Cauli³, Lorenzo Cavagna⁴, Rossella De Angelis⁵, Roberto Depascale², Giacomo Emmi⁶, Roberto Gerli⁷, Marcello Govoni⁸, Alberto Lo Gullo⁹, Simone Negrini¹⁰, Luca Quartuccio¹¹, Maurizio Rossini¹², Carlo Salvarani¹³, Paola Tomietto¹⁴, Angelo Vacca¹⁵, Margherita Zen¹⁶ and doria Andrea², ¹University of Padua, PADOVA, Italy, ²University of Padova, Padova, Italy, ³University of Cagliari, Cagliari, Italy, ⁴University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ⁵Università Politecnica delle Marche, Ancona, Italy, ⁶University of Trieste, Trieste, Italy, ⁷University of Perugia, Perugia, Italy, ⁸Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy, Ferrara, Italy, ⁹Rheumatology Unit, Papardo Hospital, Messina, Italy, ¹⁰University of Genova, Genova, Italy, ¹¹Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, ¹²Rheumatology Unit, University of Verona, Verona, Italy, ¹³Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ¹⁴Azienda Sanitaria Universitaria Giuliano Isontina, trieste, Italy, ¹⁵University of Bari, Bari, Italy, ¹⁶University of Padova, Padova, Padua, Italy
Background/Purpose: To evaluate the efficacy of belimumab on different skin and joint manifestations of the disease in a multicenter, nationwide, cohort (BeRLISS-NeJS) of patients with…
Abstract Number: 2436 • ACR Convergence 2024
Characterization of RO7507062, a CD19-Targeting T-Cell Bispecific Antibody (CD19TCB), and Design of Its Ongoing Phase 1 Trial in Systemic Lupus Erythematosus
Florian Kollert¹, Sarah Robertson², Veit Erpenbeck², Franziska Regenass-Lechner³, Remy Hallet³, Jason Neale², Cary M. Looney², Nicolas Frances², Celine Marban-Doran², Sophia Fredrika Soehrman Brossard², Laurie Millar⁴, Beki Finch⁵, Johannes Sam⁶, Benjamin A. Fisher⁷, Maria Leandro⁸, Thomas Dörner⁹, Christian Klein¹⁰ and Franz Schuler², ¹University Hospital Basel, Basel, Switzerland, ²F. Hoffmann-La Roche Ltd., Basel, Switzerland, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴F. Hoffmann-La Roche Ltd., Welwyn Garden City, England, United Kingdom, ⁵F. Hoffmann-La Roche Ltd., Welwyn Garden City, United Kingdom, ⁶F. Hoffmann-La Roche Ltd, Schlieren, Zurich, Switzerland, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸University College London, London, United Kingdom, ⁹Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ¹⁰F. Hoffman-La Roche Ltd., Schlieren, Zurich, Switzerland
Background/Purpose: CD20-directed B-cell depletion therapy shows efficacy in hematological malignancies and in multiple autoimmune indications. More recently, promising data for the use of CD19-targeted B-cell…
Abstract Number: 0008 • ACR Convergence 2024
Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
Ashley Mahne¹, Ryan Rodriguez², Jessica Wang¹, Daniel Anaya¹, Joseph K. Cheng¹, Brandon Kwong¹, Jesus Banuelos³, Peter Starokadomskyy³, Soo Park³, Candice Gibson⁴, Shouvonik Sengupta¹, Simone Sandoval¹, Jazmin Bravo³, Jeanne Flandez¹, Shairaz Shah¹, Amanda Goodsell¹, Nicole Khoshnoodi¹, Jennifer Zeng¹, Santiago Foos-Russ¹, Mario Lorente¹, Jennifer Adrian¹, Timothy Klasson¹, Yong Zhang⁵, Jessica Seitzer⁶, Birgit Schultes⁵ and Tom Van Blarcom³, ¹Kyverna Therapeutics, Inc., Emeryville, CA, ²Kyverna Therapeutics, Inc., Emerville, CA, ³Kyverna Therapeutics, Inc., Emeryville, ⁴Kyverna Therapeutics, Inc., Emerybille, ⁵Intellia Therapeutics, Inc., Cambridge, MA, ⁶Intellia Therapeutics, Inc., Cambridge
Background/Purpose: Autologous anti-CD19 chimeric antigen receptor (CAR) T cells show early clinical evidence of safety and efficacy for treating several autoimmune diseases (Müller F. N Engl…
Abstract Number: 0666 • ACR Convergence 2024
Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy
Cuiling Fan¹, Shixian Chen² and Juan Li¹, ¹Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China (People's Republic), ²Nanfang Hospital, Southern Medical University, guangzhou, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. BAFF/APRIL-targeted therapy exert therapeutic effects through the inhibition of B-cell activating factor (BAFF) and a…
Abstract Number: 1646 • ACR Convergence 2024
A Novel E3 Ligase of GILZ: Validation of a Steroid-sparing Therapeutic Target in SLE
Iolanda Miceli¹, Rochelle Sherlock², Pamela Hall², IanIan Cheang², Akshay D'Cruz³, Taylah Bennett², Terry Lim Kam Sian², Rangi Kandane-Rathnayake⁴, Eric Morand⁵ and Sarah Jones², ¹Monash University, Glen Iris, Victoria, Australia, ²Monash University, Melbourne, Australia, ³Monash University, Me, Australia, ⁴Monash University, Clayton, Victoria, Australia, ⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: SLE is primarily mediated by B cell dysregulation on a background of type I interferon (IFN) activation. This multi-faceted nature of immune defects in…
Abstract Number: 2437 • ACR Convergence 2024
Aryl Hydrocarbon Receptor as an Intrinsic Novel Checkpoint That Inhibits TLR7-induced B-cell Activation in SLE
Changming Lu¹, Jose Rubio², Hui-Chen Hsu¹ and John D. Mountz³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Hoover, AL, ³University Alabama Birmingham, Birmingham, AL
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by an increase in T-bet+ IgD−CD27− double negative 2 (DN2) B cells, attributed to heightened TLR7 signaling. Identifying…
Abstract Number: 0009 • ACR Convergence 2024
Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
Kazuki Matsuda, Shinichi Sato and Ayumi Yoshizaki, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) affects the skin and internal organs with a poor prognosis. While the exact cause remains unclear, increasing evidence indicates that B…

« Previous Page
1
…
6
7
8
9
10
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].